Beta Amyloid Inhibitors
Beta-amyloid (Aβ) inhibitors target the aggregation and accumulation of amyloid-beta peptides, which are widely considered central to the pathogenesis of Alzheimer's disease (AD) according to the 'amyloid hypothesis.' Aβ peptides are proteolytic fragments derived from the amyloid precursor protein (APP) through sequential cleavage by beta-secretase (BACE1) and gamma-secretase. In AD, Aβ peptides, particularly the 42-amino acid form (Aβ42), misfold and aggregate into toxic oligomers, fibrils, and ultimately insoluble amyloid plaques in the brain. These aggregates are believed to initiate a cascade of events leading to synaptic dysfunction, neuroinflammation, tau pathology, neuronal loss, and progressive cognitive decline. Beta-amyloid inhibitors aim to intervene at various stages of this process: by reducing Aβ production, preventing its aggregation, or enhancing its clearance from the brain. Production inhibitors include BACE1 inhibitors and gamma-secretase inhibitors or modulators, which reduce the generation of Aβ from APP. Aggregation inhibitors are designed to prevent Aβ peptides from forming toxic oligomers and fibrils. Clearance enhancers, predominantly monoclonal antibodies, promote the removal of existing Aβ aggregates.
Alzheimer's disease is the sole primary indication for Aβ inhibitors. The research progress in this field has been extensive but fraught with challenges. Several BACE1 inhibitors (e.g., verubecestat, atabecestat, lanabecestat) and gamma-secretase inhibitors (e.g., semagacestat) failed in late-stage clinical trials due to lack of efficacy, cognitive worsening, and significant side effects (e.g., affecting other gamma-secretase substrates like Notch). This led to a significant re-evaluation of the amyloid hypothesis and the timing of intervention. However, the landscape has recently shifted with the approval of anti-Aβ monoclonal antibodies. Aducanumab (Aduhelm) received controversial accelerated approval in 2021 based on its ability to reduce amyloid plaques, though clinical benefit was less clear. More recently, lecanemab (Leqembi) was approved in 2023, demonstrating a modest but statistically significant slowing of cognitive decline and substantial amyloid plaque reduction.
Donanemab, another anti-Aβ antibody targeting a modified form of Aβ, has shown promising Phase III results and is awaiting approval. These antibodies are classified as clearance enhancers, binding to specific forms of Aβ (e.g., protofibrils for lecanemab) to facilitate their removal. The failures of earlier small molecule inhibitors have largely dampened enthusiasm for secretase inhibitors, though gamma-secretase modulators are still being explored. Aggregation inhibitors remain largely in preclinical or early clinical development. A critical aspect of Aβ-targeting therapies is the timing of intervention, as it is hypothesized that Aβ pathology begins decades before clinical symptoms. Side effects of anti-Aβ antibodies include Amyloid-Related Imaging Abnormalities (ARIA), such as ARIA-E (edema/effusion) and ARIA-H (hemorrhage), requiring careful monitoring. The amyloid hypothesis, while still central, is increasingly viewed as one component of a complex disease, with tau pathology, neuroinflammation, and vascular factors also playing crucial roles.
Future strategies may involve combination therapies targeting multiple pathways. Biomarkers such as CSF Aβ42/40 ratio, PET amyloid imaging, and plasma Aβ levels are essential for diagnosis, patient selection, and monitoring treatment response.
